Chimerix, Inc.: Series F $45M

Posted in I - Series F, Q - 1Q11, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

Apr

2010

AiCuris, GmbH: Series B $74.8M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Antibacterial, X - Antiinfective, X - Antiviral, X - CMV, X - HIV, X - Hepatitis B, X - Hepatitis C

AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.

Oct

2009

Chimerix, Inc.: Series E $16M

Posted in I - Series E, Q - 3Q09, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

to top of page...